Perspectives on the management of chronic hepatitis B and C

References

• Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med.357(25), 2576–2588 (2007).
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis.8(3), 167–178 (2008).
   PubMed Web of Science ®Google Scholar
• Lui YYN, Chan HLY. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev. Anti Infect. Ther.7(3), 259–268 (2009).
   PubMed Web of Science ®Google Scholar
• Chan HL, Heathcote EJ, Marcellin P et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med.147(11), 745–754 (2007).
   PubMed Web of Science ®Google Scholar
• Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev. Anti Infect. Ther.7(3), 281–291 (2009).
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Antonakopoulos N. Treatment of hepatitis B. Gut57(1), 105–124 (2007).
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol.1950, 227–242 (2009).
   Google Scholar
• Villet S, Ollivet A, Pichoud C et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol.46(3), 531–538 (2007).
   PubMed Web of Science ®Google Scholar
• Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology131(4), 1253–1261 (2006).
   PubMed Web of Science ®Google Scholar
• Si Ahmed SN, Zoulim F. Measuring HBV resistance in clinical practice: pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Rev. Anti Infect. Ther.7(3), 309–320 (2009).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Little G, Imagawa DK. Hepatitis B immunoglobulin in preventing reinfection following liver transplantation. Expert Rev. Anti Infect. Ther.7(3), 321–328 (2009).
   PubMed Web of Science ®Google Scholar
• Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl. Int.22(4), 387–394 (2009).
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine1926, 1375–1386 (2008).
   Google Scholar
• Meier V, Ramadori G. Hepatitis C virus virology and new treatment targets. Expert Rev. Anti Infect. Ther.7(3), 329–350 (2009).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology132, 1979–1998 (2007).
   PubMed Web of Science ®Google Scholar
• Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology135, 1561–1567 (2008).
   PubMed Web of Science ®Google Scholar
• Darling JM, Fried MW. Nitazoxanide: beyond parasites toward a novel agent for hepatitis C. Gastroenterology136, 760–763 (2009).
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology136, 856–862 (2009).
   PubMed Web of Science ®Google Scholar
• Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders. Expert Rev. Anti Infect. Ther.7(3), 363–376 (2009).
   PubMed Web of Science ®Google Scholar
• Schaefer M, Hinzpeter A, Mohmand A et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-α and ribavirin: response and psychiatric side effects. Hepatology1946, 991–998 (2007).
   Google Scholar
• Ozaras R, Tahan V. Acute hepatitis C: prevention and treatment. Expert Rev. Anti Infect. Ther.7(3), 351–361 (2009).
   PubMed Web of Science ®Google Scholar
• Danta M, Brown D, Bhagani S et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS11(1921), 983–991 (2007).
   Google Scholar
• Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals – a review. Curr. Pharm. Des.1914, 1690–1697 (2008).
   Google Scholar
• Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev. Anti Infect. Ther.7(3), 293–308 (2009).
   PubMed Web of Science ®Google Scholar
• Dai CY, Huang JF, Hsieh MY et al. Insulin resistance predicts response to peginterferon-α/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol. DOI: 10.1016/j.jhep.2008.12.017 (2009) (Epub ahead of print).
   Google Scholar
• Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int.1929, 13–25 (2009).
   Google Scholar